6OUS

Structure of fusion glycoprotein from human respiratory syncytial virus

Summary for 6OUS

• Entry DOI: 10.2210/pdb6ous/pdb
• Descriptor: Fusion glycoprotein F2, Fusion glycoprotein F1 fused with Fibritin trimerization domain, RB1 Fab Heavy Chain, ... (6 entities in total)
• Functional Keywords: antibody, rsv, neutralizing, viral protein, viral protein-immune system complex, viral protein/immune system
• Biological source: Human respiratory syncytial virus A2; More
• Total number of polymer chains: 24
• Total formula weight: 623853.31

Authors

Su, H.P. (deposition date: 2019-05-05, release date: 2019-10-30, Last modification date: 2024-10-23)

Primary citation

Tang, A.,Chen, Z.,Cox, K.S.,Su, H.P.,Callahan, C.,Fridman, A.,Zhang, L.,Patel, S.B.,Cejas, P.J.,Swoyer, R.,Touch, S.,Citron, M.P.,Govindarajan, D.,Luo, B.,Eddins, M.,Reid, J.C.,Soisson, S.M.,Galli, J.,Wang, D.,Wen, Z.,Heidecker, G.J.,Casimiro, D.R.,DiStefano, D.J.,Vora, K.A.
A potent broadly neutralizing human RSV antibody targets conserved site IV of the fusion glycoprotein.
Nat Commun, 10:4153-4153, 2019

PubMed Abstract: Respiratory syncytial virus (RSV) infection is the leading cause of hospitalization and infant mortality under six months of age worldwide; therefore, the prevention of RSV infection in all infants represents a significant unmet medical need. Here we report the isolation of a potent and broadly neutralizing RSV monoclonal antibody derived from a human memory B-cell. This antibody, RB1, is equipotent on RSV A and B subtypes, potently neutralizes a diverse panel of clinical isolates in vitro and demonstrates in vivo protection. It binds to a highly conserved epitope in antigenic site IV of the RSV fusion glycoprotein. RB1 is the parental antibody to MK-1654 which is currently in clinical development for the prevention of RSV infection in infants.

PubMed: 31515478
DOI: 10.1038/s41467-019-12137-1

Experimental method

X-RAY DIFFRACTION (3.4 Å)